Erratum: Detection of cervical precancer and cancer in a hospital population: Benefits of testing for human papillomavirus (European Journal of Cancer (2004) 40 (1225-1232) PII: S0959-8049(04)00132-7 and DOI: 10.1016/j.ejca.2004.01.021);Detection of cervical precancer and cancer in a hospital population: Benefits of testing for human papillomavirus

European Journal of Cancer

Volumn 40, Issue 8, 2004, Pages 1225-1232

  Dalstein, V ^a   Riethmuller, D ^b   Sautiere J L ^b   Pretet J L ^a   Kantelip, B ^b   Schaal, J P ^b   Mougin, C ^a,b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia (CIN); Human papillomavirus (HPV); Hybrid capture II (HCII); Pap smear; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PAPANICOLAOU TEST; PRECANCER; PREDICTION; PRIORITY JOURNAL; TUMOR BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

EID: 1942424079     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.08.014     Document Type: Erratum

References (31)

1. Weidmann C., Schaffer P., Hédelin G.H.et al. L'incidence du cancer du col de l'utérus régresse régulièrement en France. Bull. Epidémiol. Hebdomadaire. 5:1998;17-19.
2. Sasieni P. Cervical sampling devices. Br. Med. J. 313:1996;1275-1276.
3. Stoler M.H., Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations. realistic estimates from the ASCUS-LSIL Triage Study JAMA. 285:2001;1500-1505.
4. Papillo J.L., Zarka M.A., St John T.L. Evaluation of the ThinPrep Pap test in clinical practice. A seven-month, 16,314-case experience in northern Vermont. Acta Cytol. 42:1998;203-208.
5. Bernstein S.J., Sanchez-Ramos L., Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears. a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy Am. J. Obstet. Gynecol. 185:2001;308-317.
6. Bosch F.X., Manos M.M., Muñoz N.et al. Prevalence of human papillomavirus in cervical cancer. a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group J. Natl. Cancer Inst. 87:1995;796-802.
7. Walboomers J.M., Jacobs M.V., Manos M.M.et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19.
8. Wallin K.L., Wiklund F., Angstrom T.et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl. J. Med. 341:1999;1633-1638.
9. Dalstein V., Riethmuller D., Prétet J.L.et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions. A longitudinal French cohort study Int. J. Cancer. 106:2003;396-403.
10. Riethmuller D., Gay C., Bertrand X.et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn. Mol. Pathol. 8:1999;157-164.
11. Bory J.P., Cucherousset J., Lorenzato M.et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions. a longitudinal study of 3,091 women Int. J. Cancer. 102:2002;519-525.
12. Cuzick J., Beverley E., Ho L.et al. HPV testing in primary screening of older women. Br. J. Cancer. 81:1999;554-558.
13. Schneider A., Hoyer H., Lotz B.et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int. J. Cancer. 89:2000;529-534.
14. Schiffman M., Herrero R., Hildesheim A.et al. HPV DNA testing in cervical cancer screening. results from women in a high-risk province of Costa Rica JAMA. 283:2000;87-93.
15. Ratnam S., Franco E.L., Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev. 9:2000;945-951.
16. Clavel C., Masure M., Bory J.P.et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions. a study of 7932 women Br. J. Cancer. 84:2001;1616-1623.
17. Kulasingam S.L., Hughes J.P., Kiviat N.B.et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. comparison of sensitivity, specificity, and frequency of referral JAMA. 288:2002;1749-1757.
18. Petry K.U., Bohmer G., Iftner T.et al. Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia. Am. J. Obstet. Gynecol. 186:2002;28-34.
19. Manos M.M., Kinney W.K., Hurley L.B.et al. Identifying women with cervical neoplasia. using human papillomavirus DNA testing for equivocal Papanicolaou results JAMA. 281:1999;1605-1610.
20. Solomon D., Schiffman M., Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. baseline results from a randomized trial J. Natl. Cancer Inst. 93:2001;293-299.
21. Nobbenhuis M.A., Meijer C.J., van den Brule A.J.et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br. J. Cancer. 84:2001;796-801.
22. Meijer C.J., Helmerhorst T.J., Rozendaal L., van der Linden J.C., Voorhorst F.J., Walboomers J.M. HPV typing and testing in gynaecological pathology. has the time come? Histopathology. 33:1998;83-86.
23. Cuzick J. Time to consider HPV testing in cervical screening. Ann. Oncol. 12:2001;1511-1514.
24. Cain J.M., Howett M.K. Preventing cervical cancer. Science. 288:2000;1753-1755.
25. Herbst A.L., Pickett K.E., Follen M., Noller K.L. The management of ASCUS cervical cytologic abnormalities and HPV testing. a cautionary note Obstet. Gynecol. 98:2001;849-851.
26. Monnet E., Carbillet J.P., Meslans Y., Petitjean A., Gautier C.P. [Participation of women in cervical cancer screening. Results of the first 5 years of a pilot program in the province of Doubs]. Presse. Med. 28:1999;2093-2097.
27. Schaffer P., Sancho-Garnier H., Fender M.et al. Cervical cancer screening in France. Eur. J. Cancer. 36:2000;2215-2220.
28. Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int. J. Cancer. 54:1993;563-570.
29. Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J.et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 358:2001;1782-1783.
30. Rozendaal L., Walboomers J.M., van der Linden J.C.et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int. J. Cancer. 68:1996;766-769.
31. Cuzick J., Szarewski A., Cubie G.et al. Management of women who test positive for high-risk types of human papillomavirus. the HART study Lancet. 362:2003;1871-1876.